← FDA DRUG APPROVALS

FDA NDA · NDA021396

PREMPRO/PREMPHASE

Sponsor: WYETH AYERST

APPLICATION
NDA021396
TYPE
NDA
ORIGINAL APPROVAL
2003-06-04
LATEST ACTION
2003-06-04
ROUTE
Oral
DOSAGE FORM
Tablet
MARKETING STATUS
Prescription

Products

PREMPRO/PREMPHASEPrescription
CONJUGATED ESTROGENS/MEDROXYPROGESTERONE ACETATE 0.45MG/1.5MG & 0.3MG/1.5MG · Tablet · Oral

Approval history

2003-06-04Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →